Neupogen (Filgrastim)

Filgrastim, the active ingredient in Neupogen, is a granulocyte colony‑stimulating factor presented as an injectable solution for subcutaneous use. It treats chemotherapy‑induced neutropenia, neutropenia associated with bone‑marrow transplantation, severe chronic neutropenia, and supports peripheral blood stem‑cell mobilization.

GNH USA supplies Neupogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Neupogen (filgrastim) is a granulocyte colony‑stimulating factor used to manage neutropenia in several clinical settings.

- Chemotherapy‑induced neutropenia: reduces the duration of neutropenia and lowers infection risk in patients receiving cytotoxic chemotherapy. - Neutropenia associated with bone‑marrow transplantation: accelerates neutrophil recovery after transplant procedures. - Severe chronic neutropenia: increases absolute neutrophil count to reduce infection susceptibility. - Peripheral blood stem‑cell mobilization: enhances mobilization of CD34+ stem cells for collection prior to autologous transplantation.

Common Side Effects: - Bone pain: aching discomfort often reported in long bones. - Injection‑site reactions: redness, swelling, or mild tenderness at the subcutaneous site. - Fever: transient elevation of body temperature. - Headache: mild to moderate head discomfort.

Serious or Rare Side Effects: - Splenic rupture: sudden abdominal pain with signs of internal bleeding. - Acute respiratory distress syndrome: severe breathing difficulty requiring urgent care. - Anaphylaxis: rapid onset of allergic symptoms such as hives, swelling, and airway compromise. - Capillary leak syndrome: hypotension, edema, and hypoalbuminemia indicating vascular leakage.

Before initiating therapy, clinicians should consider several safety measures. - Baseline neutrophil count: confirm indication and establish a reference level. - CBC monitoring: regularly assess neutrophil response and detect leukocytosis. - Splenomegaly evaluation: avoid use in patients with known enlarged spleen. - Sickle‑cell disease caution: monitor for vaso‑occlusive events. - Discontinue on severe allergic reaction: stop immediately if anaphylaxis occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Filgrastim may interact with other therapies that affect the immune system or blood counts.

Major Interactions (Avoid): - Concurrent cytotoxic chemotherapy causing profound myelosuppression: may blunt filgrastim efficacy. - Systemic corticosteroids: can diminish neutrophil response to filgrastim.

Moderate Interactions (Monitor Closely): - Quinolone antibiotics: may mask signs of infection while neutrophils rise. - Immunosuppressants (e.g., cyclosporine): could alter neutrophil function. - Live vaccines: reduced vaccine efficacy; schedule vaccination appropriately.